SLE mice treated with leptin antagonist had an increase in the percentage of CD4+ T cells (49.9 ± 2.7% of total CD3 vs. 63.3 ± 1.8 of total CD3 and a significant decrease in the percentage of DN T cells (SLE-vehicle: 23.8 ± 2.2% of total CD3 vs. SLE-LA: 13.2 ± 2.5%, of total CD3, P=0.0004). Here, CD4 is linked to systemic lupus erythematosus.